Cargando…

Adult-onset Still's disease after mRNA COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Magliulo, Daniel, Narayan, Soumya, Ue, Frances, Boulougoura, Afroditi, Badlissi, Fadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298008/ https://www.ncbi.nlm.nih.gov/pubmed/34316726 http://dx.doi.org/10.1016/S2665-9913(21)00219-8

Ejemplares similares

Adult-onset Still's disease following COVID-19 vaccination
por: Leone, Flavia, et al.
Publicado: (2021)

First manifestation of adult-onset Still's disease after COVID-19
por: Bamidis, Anna D, et al.
Publicado: (2021)

Adult-onset Still's disease following mRNA COVID-19 vaccination
por: Sharabi, Amir, et al.
Publicado: (2021)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
por: Heymans, Stephane, et al.
Publicado: (2021)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

Adult-onset Still’s Disease after BNT162b2 mRNA COVID-19 Vaccine
por: Park, Seong Yeon, et al.
Publicado: (2021)

Vaccine hope is still alive
por: Wilson, Clare
Publicado: (2020)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19
por: Richardson, Christopher D
Publicado: (2022)

CS-2034 mRNA vaccine: a new option for COVID-19 infection?
por: Zhang, Ruiqi, et al.
Publicado: (2023)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
por: Iwata, Masahiro, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

The problem of selection bias in studies of pre-mRNA splicing
por: Dwyer, Zachary W., et al.
Publicado: (2023)

SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
por: Füessl, Louise, et al.
Publicado: (2022)

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

Emerging links between m(6)A and misregulated mRNA methylation in cancer
por: Jaffrey, Samie R., et al.
Publicado: (2017)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia
por: Wood, Nicholas, et al.
Publicado: (2023)

Flare of adult-onset Still’s disease following mRNA COVID-19 vaccination: a case report and review of literature
por: Kim, Ji-Won, et al.
Publicado: (2022)

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
por: Waissengrin, Barliz, et al.
Publicado: (2021)

Still no flying cars
por: Petsko, Gregory A
Publicado: (2003)

Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them!
por: Gronbeck, Christian, et al.
Publicado: (2021)

Intravenous vitamin C in adults with sepsis in the intensive care unit: still LOV’IT?
por: Stoppe, Christian, et al.
Publicado: (2022)

Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3r1075hrljgrgg6gsm0f2fhki2